Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

"MariTide and all of the GLP-1 medications have similar side effect profiles: nausea, vomiting, abdominal pain, constipation and less commonly pancreatic irritation," says Dr. Nadler.

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its Outperform rating, BMO Capital lowered its price target for Amgen Inc. (NASDAQ:AMGN) ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly injection treatment.

In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm, and up to ~17% average ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

MariTide: Weight Loss With Type 2 Diabetes (Amgen MariTide Update - 11/26/24) Study participants lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug demonstrated 20% average ...

--Amgen today announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to ...